WO2014073209A1 - 角結膜障害の治療剤 - Google Patents
角結膜障害の治療剤 Download PDFInfo
- Publication number
- WO2014073209A1 WO2014073209A1 PCT/JP2013/006563 JP2013006563W WO2014073209A1 WO 2014073209 A1 WO2014073209 A1 WO 2014073209A1 JP 2013006563 W JP2013006563 W JP 2013006563W WO 2014073209 A1 WO2014073209 A1 WO 2014073209A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- corneal
- therapeutic agent
- keratitis
- rarγ agonist
- agonist
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a therapeutic agent for keratoconjunctival disorder containing a RAR ⁇ agonist as an active ingredient.
- the cornea is a transparent avascular tissue with a diameter of about 1 cm covering the front of the eyeball, and the conjunctiva is the mucous membrane covering the surface of the eyeball behind the corneal margin and the back of the eyelid, which play important functions in vision. It is known that if any disorder occurs, the visual function is seriously affected.
- a keratoconjunctival disorder caused by various diseases such as corneal ulcer, keratitis, and dry eye is caused by delay in repair of a disorder caused by some reason such as an external disorder or a prolonged disorder. Since the cornea and the conjunctiva are a continuous tissue, these diseases can adversely affect the normal construction of each other's epithelium, and even the structure and function of the corneal stroma and the endothelium.
- Collagen (especially type I collagen) is known as one of the typical matrix components constituting the corneal parenchymal tissue, and a dysfunction associated with matrix degradation occurs in a disease caused by keratoconjunctival disorder. Therefore, suppressing the degradation of collagen (particularly type I collagen) is considered effective for diseases caused by keratoconjunctival disorders.
- scar tissue often formed after inflammation subsides may impair visual function. Therefore, as with the above-described suppression of collagen degradation, if it is possible to suppress the contraction of collagen, it is considered effective for scar formation and contraction (hereinafter collectively referred to as “scar formation”).
- Patent Document 1 describes that all-trans-retinoic acid (hereinafter sometimes referred to as ATRA) promotes corneal regeneration, but its action is weak and the detailed mechanism is not clarified.
- ATRA all-trans-retinoic acid
- ATRA is an agonist of retinoic acid receptor (hereinafter sometimes referred to as RAR), but does not have selectivity for RAR subtypes RAR ⁇ , RAR ⁇ and RAR ⁇ , so each RAR subtype for cornea regeneration action The contribution of is unknown.
- RAR is involved in various actions such as proliferation, morphogenesis and differentiation in many cells such as inflammation, immunity and structural cells, and the distribution of RAR subtypes is determined in mammalian tissues and organs. It is confirmed that there is a difference depending on.
- the compound having RAR agonist activity has specificity or selectivity for subtypes, leading to a reduction in the risk of side effects.
- Patent Documents 2 and 3 include RAR agonist (E) -4- (2- ⁇ 3-[(1H-pyrazol-1-yl) methyl] -5,5,8,8-tetramethyl-5, 6,7,8-Tetrahydronaphthalen-2-yl ⁇ vinyl) benzoic acid and its derivatives are disclosed.
- Patent Document 2 discloses (E) -4- (2- ⁇ 3-[(1H-pyrazol-1-yl) methyl] -5,5,8,8-tetramethyl-5,6,7, 8-tetrahydronaphthalen-2-yl ⁇ vinyl) benzoic acid is described to be useful for emphysema, cancer, and skin diseases, and Patent Document 3 describes that it is useful for neuropathic pain. ing.
- Non-Patent Document 1 describes that RAR agonist 6- [3- (1-adamantyl) -4-hydroxyphenyl] -2-naphthalene acid induces apoptosis of lung cancer cells. .
- Patent Document 4 describes 3-fluoro-4- [2-hydroxy-2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2- Yl) acetylamino] benzoic acid is described as being useful for muscle repair or regeneration.
- An object of the present invention is to provide a therapeutic agent having a keratoconjunctival disorder inhibitory action and high safety based on subtype selectivity.
- R667 hereinafter sometimes referred to as "RAR ⁇ agonist A”
- RAR ⁇ agonist A a pharmacological test using cells and subconjunctival fibroblasts, it showed a strong collagen degradation inhibitory action, and also showed a significant collagen shrinkage inhibitory action, so it exhibited an excellent improvement effect on keratoconjunctival disorders, At the same time, it has been found that it exhibits an excellent improvement effect on scar formation associated with keratoconjunctival disorder.
- RAR ⁇ agonists such as 6- [3- (1-adamantyl) -4-hydroxyphenyl] -2-naphthalene acid (CD437: hereinafter sometimes referred to as “RAR ⁇ agonist B”), 3-fluoro-4 -[2-Hydroxy-2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) acetylamino] benzoic acid (BMS961: hereinafter referred to as “RAR ⁇ agonist C”)
- RAR ⁇ agonist C 3-fluoro-4 -[2-Hydroxy-2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) acetylamino] benzoic acid
- the present invention relates to a therapeutic agent for keratoconjunctival disorders containing [1] RAR ⁇ agonist as an active ingredient, and [2] RAR ⁇ agonist (E) -4- (2- ⁇ 3-[(1H-pyrazole- 1-yl) methyl] -5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl ⁇ vinyl) benzoic acid, 6- [3- (1-adamantyl) -4 -Hydroxyphenyl] -2-naphthalene acid or 3-fluoro-4- [2-hydroxy-2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl ) Acetylamino] benzoic acid, its ester or its salt, the therapeutic agent according to [1] above, or [3] keratoconjunctival disorder is corneal ulcer, corneal epithelial detachment, keratitis,
- the RAR ⁇ agonist that is an active ingredient of the therapeutic agent for keratoconjunctival disorder of the present invention strongly suppresses collagen degradation in the keratoconjunctiva, thereby causing corneal ulcer, corneal epithelial detachment, keratitis, dry eye, conjunctivitis, chronic superficial keratitis , Corneal fistula, prolonged corneal disorder, punctate superficial keratopathy, corneal epithelial defect, conjunctival epithelial defect, dry keratoconjunctivitis, upper ring keratoconjunctivitis, filiform keratoconjunctivitis, infectious keratitis, non-infectious keratitis, infectious It is useful as a therapeutic agent for keratoconjunctival disorders such as conjunctivitis or non-infectious conjunctivitis.
- the RAR ⁇ agonist which is an active ingredient of the therapeutic agent for keratoconjunctival disorder of the present invention, can be used as a therapeutic agent for corneal scarring or conjunctival scarring associated with keratoconjunctival disorder by strongly suppressing collagen contraction in the keratoconjunctiva. Useful.
- the vertical axis represents the amount of hydroxyproline ( ⁇ g) per well when the RAR ⁇ agonist and the stimulant are added, where the amount of hydroxyproline ( ⁇ g) per well when the RAR ⁇ agonist and the stimulant are not added is 1.
- the ratio (Ratio) is shown. In the figure, “ ⁇ ” indicates that there is a statistically significant difference (p ⁇ 0.05). It is a figure which shows the relationship between the density
- FIG. 5A shows the expression and activation of MMP-3
- FIG. 5B shows the expression and activation of MMP-2 and MMP-9.
- LPS lipopolysaccharide
- RAR gamma
- the upper is the result of adding only the solution not containing the RAR ⁇ agonist A (R667) of the present invention
- the lower (0.1% R667) is the result of adding the solution containing the RAR ⁇ agonist A (R667).
- the therapeutic agent for keratoconjunctival disorder of the present invention is not particularly limited as long as it contains a RAR ⁇ agonist as an active ingredient, and the RAR ⁇ agonist of the present invention is an RAR ⁇ receptor compared to the RAR ⁇ receptor and the RAR ⁇ receptor.
- RAR ⁇ agonists include (E) -4- (2- ⁇ 3-[(1H-pyrazol-1-yl) methyl] -5,5,8,8-tetramethyl represented by the following formula (I): -5,6,7,8-tetrahydronaphthalen-2-yl ⁇ vinyl) benzoic acid (R667) and 6- [3- (1-adamantyl) -4-hydroxyphenyl] represented by the following formula (II) -2-naphthalene acid (CD437) or 3-fluoro-4- [2-hydroxy-2- (5,5,8,8-tetramethyl-5,6,7, represented by the following formula (III): 8-tetrahydronaphthalen-2-yl) acetylamino] benzoic acid (BMS961) and (2E) -3- (4-carboxylphenyl) -1- (5,5,8, represented by the following formula (IV): 8-tetramethyl-5,6,7,8- Trahydronaphthalen-2-yl)
- a method for treating keratoconjunctival disorders characterized by administering the RAR ⁇ agonist of the present invention to a subject, and a RAR ⁇ agonist of the present invention for use as a therapeutic agent for keratoconjunctival disorders And the use of the RAR ⁇ agonist of the present invention in the preparation of a therapeutic agent for keratoconjunctival disorders.
- the RAR ⁇ agonist A, its ester or its salt, which is one of the active ingredients of the therapeutic agent for keratoconjunctival disorder of the present invention, is a known compound described in Patent Document 2, and the method described in Patent Document 2
- Patent Document 2 it is also possible to purchase a commercial product.
- An example of such a commercial product is a product name: Palovarotene manufactured by Shanghai Haoyuan Chemexpress.
- RAR ⁇ agonist B is described in Non-Patent Document 1 and Patent Document 4
- RAR ⁇ agonist C is described in Patent Document 4
- RAR ⁇ agonists D and E are described in the following documents (Shimono K Et al., Nat Med. 17 (4): 454-460 (2011)), and such compounds, their esters or their salts can be prepared according to conventional methods.
- commercial products can be purchased.
- examples of commercially available RAR ⁇ agonist B include Abcam Corporation product name: CD437 (ab141305) and Tocris® Bioscence product name: CD437
- RAR ⁇ agonist C includes Tocris® Bioscence product name: BMS961.
- Examples of the RAR ⁇ agonist E include Santa® Cruz® biotechnology: product name CD1530 and Tocris® Bioscence® product name: CD1530.
- esters of the RAR ⁇ agonists A, B, C, D, and E which are active ingredients of the therapeutic agent for keratoconjunctival disorders of the present invention, are RAR ⁇ agonist A, by reaction with an enzyme or the like under physiological conditions in vivo. There is no particular limitation as long as it is an ester that can be converted into B, C, D, and E.
- esters examples include esters with primary alcohols such as methanol, ethanol, propanol, hexanol, or dodecanol; isopropanol, s-butanol, or Examples include esters with secondary alcohols such as 1-ethylpropanol; esters with tertiary alcohols such as t-butanol or 1-methyl-1-ethylpropanol; or esters with amino alcohols such as 2-aminoethanol. .
- the above ester can be produced from the RAR ⁇ agonists A, B, C, D, E or synthetic intermediates thereof by a known method.
- the salt of the RAR ⁇ agonists A, B, C, D, and E, which is an active ingredient of the therapeutic agent for keratoconjunctival disorder of the present invention, is not particularly limited as long as it is a pharmaceutically acceptable salt.
- an inorganic acid salt such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or phosphate; or acetate, trifluoroacetate, benzoate , Oxalate, malonate, succinate, maleate, fumarate, tartrate, citrate, methanesulfonate, ethanesulfonate, trifluoromethanesulfonate, benzenesulfonate
- Organic acid salts such as p-toluenesulfonate, glutamate or aspartate, or
- basic salts such as sodium, potassium, calcium or magnesium salts
- Inorganic salts such as ammonium salts; metal salts organic amine salts
- corneal and conjunctival disorders refer to those in which the cornea or conjunctiva has been damaged due to various factors such as tear abnormalities, metabolic abnormalities, external disorders, etc., for example, corneal ulcers, corneal epithelial detachment, Keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal fistula, persistent keratopathy, punctate superficial keratopathy, corneal epithelial defect, conjunctival epithelial defect, dry keratoconjunctivitis, limbal keratoconjunctivitis, filiform keratoconjunctivitis, infection Keratitis, non-infectious keratitis, infectious conjunctivitis, non-infectious conjunctivitis, and the like, and exhibit an excellent improvement effect due to the action of inhibiting collagen degradation.
- corneal ulcers corneal epithelial detachment
- Keratitis dry eye
- corneal scarring (scarring in the cornea) and conjunctival scarring (scarring in the conjunctiva) associated with corneal and conjunctival disorders are also cited as keratoconjunctival disorders, and an excellent improvement effect due to the collagen shrinkage inhibiting action Play.
- the therapeutic agent for keratoconjunctival disorders of the present invention is produced by mixing with an appropriate pharmacologically acceptable additive, tablet, capsule, powder, syrup, granule, fine granule, pill, Liquid, suspension, emulsion, percutaneous absorption, suppository, ointment (preferably eye ointment), lotion, inhalation, injection, etc., orally or parenterally (intravenous administration, intramuscular Administration, intraperitoneal administration, transdermal administration, transrespiratory administration, intradermal administration or subcutaneous administration).
- an appropriate pharmacologically acceptable additive tablet, capsule, powder, syrup, granule, fine granule, pill, Liquid, suspension, emulsion, percutaneous absorption, suppository, ointment (preferably eye ointment), lotion, inhalation, injection, etc., orally or parenterally (intravenous administration, intramuscular Administration, intraperitoneal administration, transdermal administration, transre
- compositions are produced by a known method using additives such as excipients, lubricants, binders, disintegrants, emulsifiers, stabilizers, flavoring agents, or diluents.
- Excipients include, for example, organic excipients or inorganic excipients.
- organic excipient include sugar derivatives such as lactose, sucrose, glucose, mannitol or sorbitol; starch derivatives such as corn starch, potato starch, ⁇ -starch or dextrin; cellulose derivatives such as crystalline cellulose; gum arabic; Dextran; or pullulan and the like.
- inorganic excipients include light anhydrous silicic acid; or sulfates such as calcium sulfate.
- Lubricants include, for example, stearic acid; stearic acid metal salts such as calcium stearate or magnesium stearate; talc; colloidal silica; waxes such as beeswax or gallow; boric acid; adipic acid; sulfate such as sodium sulfate; glycol Fumaric acid; sodium benzoate; D, L-leucine; sodium lauryl sulfate; silicic acids such as anhydrous silicic acid or silicic acid hydrate; or starch derivatives in the above-mentioned excipients.
- binder examples include hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, macrogol, and compounds shown by the above-mentioned excipients.
- Disintegrants include, for example, cellulose derivatives such as low substituted hydroxypropylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium or internally crosslinked carboxymethylcellulose calcium; crosslinked polyvinylpyrrolidone; or chemically modified starch such as carboxymethyl starch or sodium carboxymethyl starch Or a cellulose derivative etc. are mentioned.
- the emulsifier is, for example, colloidal clay such as bentonite or bee gum; an anionic surfactant such as sodium lauryl sulfate; a cationic surfactant such as benzalkonium chloride; or polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester Or nonionic surfactants, such as sucrose fatty acid ester, etc. are mentioned.
- Stabilizers include, for example, parahydroxybenzoates such as methylparaben or propylparaben; alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol; benzalkonium chloride; phenols such as phenol or cresol; thimerosal; acetic anhydride Or sorbic acid.
- parahydroxybenzoates such as methylparaben or propylparaben
- alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol
- benzalkonium chloride phenols such as phenol or cresol
- thimerosal acetic anhydride Or sorbic acid.
- sweeteners such as saccharin sodium or aspartame
- acidulants such as citric acid, malic acid or tartaric acid
- flavors such as menthol, lemon extract or orange extract.
- Diluents are compounds that are usually used as diluents, such as lactose, mannitol, glucose, sucrose, calcium sulfate, hydroxypropylcellulose, microcrystalline cellulose, water, ethanol, polyethylene glycol, propylene glycol, glycerol, Examples thereof include starch, polyvinyl pyrrolidone, and mixtures thereof.
- the therapeutic agent for keratoconjunctival disorders of the present invention includes eye drops in addition to the above-mentioned dosage forms.
- eye drops in addition to the above-mentioned dosage forms.
- an isotonic agent, buffer, pH adjuster, solubilizer, thickener, stabilizer, preservative (preservative), etc. as additives.
- a stable eye drop can be obtained by adding a pH adjuster, a thickener, a dispersant and the like to suspend the drug.
- isotonic agent examples include glycerin, propylene glycol, sodium chloride, potassium chloride, sorbitol, mannitol and the like.
- buffer examples include phosphoric acid, phosphate, citric acid, acetic acid, and ⁇ -aminocaproic acid.
- pH adjuster examples include hydrochloric acid, citric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide, boric acid, borax, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium carbonate or sodium hydrogen carbonate. Etc.
- solubilizer examples include polysorbate 80, polyoxyethylene hydrogenated castor oil 60, macrogol 4000, and the like.
- thickener and dispersant examples include cellulose-based polymers such as hydroxypropylmethylcellulose or hydroxypropylcellulose; polyvinyl alcohol; or polyvinylpyrrolidone, and examples of the stabilizer include edetic acid or sodium edetate. Etc.
- preservatives examples include general-purpose sorbic acid, potassium sorbate, benzalkonium chloride, benzethonium chloride, methyl paraoxybenzoate, propyl paraoxybenzoate or chlorobutanol. It can also be used in combination.
- the pH of the eye drop may be within the range acceptable for ophthalmic preparations, but is preferably set to 4.0 to 8.5.
- an ointment preferably an eye ointment
- a commonly used base such as white petrolatum or liquid paraffin.
- the dose of the therapeutic agent for keratoconjunctival disorder of the present invention can be appropriately changed according to the dosage form, the severity of the symptoms of the patient to be administered, age, weight, judgment of the doctor, etc.
- the active ingredient concentration can be administered once or several times a day.
- an active ingredient concentration of 0.001 to 1% (W / W) can be administered once or several times a day.
- dimethylsulfoxide solution (R667 concentration: 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM) of RAR ⁇ agonist A (R667) in MEM medium or dimethylsulfoxide solution without RAR ⁇ agonist A as a control, as a stimulant IL-1 ⁇ (Product No. 201-LB-005; manufactured by R & D systems) 10 ng (final concentration 10 ng / ml) and Plasgenogen (product number P9156; Sigma) 60 ⁇ g (final concentration 60 ⁇ g / ml) were added first.
- the prepared collagen gel was overlaid, and culture (37 ° C., 5% CO 2 condition) was started.
- RAR ⁇ agonist A exhibited a collagen degradation inhibitory action in the keratoconjunctiva in a dose-dependent manner.
- RAR ⁇ agonist A 100 mg in 100 ml of eye drops Sodium chloride 800mg Polysorbate 80 Appropriate amount Disodium hydrogen phosphate Appropriate amount Sodium dihydrogen phosphate Appropriate amount Sterilized purified water Appropriate amount RAR ⁇ agonist A and the other components described above are added to sterile purified water, and these are mixed well to prepare an ophthalmic solution.
- the concentration is 0.05% (W / V), 0.3% (W / V), 0.5% (W / V) or 1% (W / V) ) Eye drops.
- RAR ⁇ agonist A 1 mg in 100 mg tablet Lactose 66.4mg Corn starch 20mg Carboxymethylcellulose calcium 6mg Hydroxypropylcellulose 6mg Magnesium stearate 0.6mg RAR ⁇ agonist A, corn starch and lactose are mixed in a blender, carboxymethylcellulose calcium and hydroxypropylcellulose are added to the mixture, granulated, and the resulting granules are dried and sized. Add magnesium acid, mix and tablet with tableting machine. Moreover, the tablet whose content in 100 mg is 0.1 mg, 10 mg, or 50 mg can be prepared by changing the addition amount of RAR ⁇ agonist A or the like.
- Test example 3D collagen gel contraction inhibition test of various primary cells derived from normal rabbits by RAR ⁇ agonist A 3D collagen gel contraction using primary subconjunctival fibroblasts and primary keratocytes, according to the method of Nishida et al. The inhibitory effect of the test compound on the was evaluated.
- Example 2 Primary subconjunctival fibroblasts were grown and detached from the culture slide, washed, and then a cell suspension was prepared.
- the obtained suspension (1.1 ⁇ 10 7 cells / ml MEM), type I collagen solution (5 mg / ml), 10 ⁇ MEM, Restitution Buffer, and water were added at 0.2: 7: 1.
- the mixture was mixed on ice at 1: 1.8 (volume ratio), 0.5 ml of this mixed solution was seeded on a culture dish coated with 1% BSA, and incubated at 37 ° C. for 1 hour to prepare a collagen gel.
- the gel diameter was measured in the same manner as the primary subconjunctival fibroblasts. The results are shown in FIG.
- RAR ⁇ agonist A suppresses not only collagen degradation but also collagen gel contraction by TGF using subconjunctival fibroblasts and corneal parenchymal cells. This is because RAR ⁇ agonist A contributes to collagen turnover and has the effect of suppressing tissue remodeling after inflammation, bleeding, infection, surgery, trauma, etc. in the eye tissue, that is, fibrosis and scarring It shows that.
- Test example Three-dimensional collagen gel degradation inhibition test of normal rabbit-derived primary corneal parenchymal cells by RAR ⁇ agonist A, B, or C Using primary keratocytes, the same as in Example 1 according to the method of Nishida et al. The inhibitory effect of the test compound on the three-dimensional collagen gel degradation was evaluated by the method.
- Example 2 In the same manner as in Example 1, primary corneal stromal cells were grown and detached from the culture slide, washed, and then a cell suspension was prepared. The obtained suspension (1.1 ⁇ 10 7 cells / ml MEM), type I collagen solution (5 mg / ml), 10 ⁇ MEM, Restitution Buffer, and water were added at 0.2: 7: 1. The mixture was mixed on ice at 1: 1.8 (volume ratio), 0.5 ml of this mixed solution was seeded on a culture dish coated with 1% BSA, and incubated at 37 ° C. for 1 hour to prepare a collagen gel.
- MMP-1, 2, 3 and 9 secretion and expression of matrix metalloproteinase (MMP), a proteolytic enzyme, is involved in the degradation of type I collagen It is believed that Therefore, the suppression of the expression and activation of MMP-1, 2, 3 and 9 by RAR ⁇ agonist A was examined.
- MMP matrix metalloproteinase
- RAR ⁇ agonist A R667 concentration: 1 ⁇ 10 ⁇ 6 ⁇ M, 1 ⁇ 10 ⁇ 5 ⁇ M, 1 ⁇ 10 ⁇ 4 ⁇ M, 1 ⁇ 10 ⁇ 3 ⁇ M, 1 ⁇ 10 ⁇ 2
- Dex dexamethasone
- IL-1 ⁇ 0.1 ng / ml
- the results are shown in FIG. 4A.
- the band of the non-active Pro-MMP-1, Pro-MMP-3 and the active MMP-1 and MMP-3 is attenuated depending on the concentration of RAR ⁇ agonist A, and RAR ⁇ agonist A is concentration-dependent. In particular, it was revealed that the expression and activation of MMP-1 and MMP-3 were suppressed.
- Results are shown in FIG. 4B.
- Inactive Pro-MMP-2, Pro-MMP-9 and active MMP-2 and MMP-9 all have a band-dependent attenuation depending on the concentration of RAR ⁇ agonist A, and RAR ⁇ agonist A is concentration-dependent. In particular, it was revealed that the expression and activation of MMP-2 and MMP-9 were suppressed.
- RAR ⁇ agonist A R667: 0.1%, 24 mM
- a micropipette twice after injection
- four times a day until 10 days thereafter 1. 50 ⁇ l of 1% PBS / 0.1% polysorbate 80 solution was instilled.
- 0.1% PBS / 0.1% polysorbate 80 solution 0.1% PBS / 0.1% polysorbate 80 solution (Vehicle) containing no RAR ⁇ agonist A was similarly administered.
- FIG. 5 shows a representative example of the case where RAR ⁇ agonist A is administered and the control.
- FIG. 5 corneal turbidity and ulceration were observed in the upper control (Vehicle), but corneal turbidity and ulceration were not observed when the lower RAR ⁇ agonist A was administered (0.1% R667).
- Agonist A was found to suppress corneal opacity and ulceration.
- the RAR ⁇ agonist which is an active ingredient of the therapeutic agent for keratoconjunctival disorder of the present invention, strongly suppresses collagen degradation, thereby causing corneal ulcer, corneal epithelial detachment, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, cornea Hemorrhoids, prolonged keratopathy, punctate superficial keratopathy, corneal epithelial defect, conjunctival epithelial defect, dry keratoconjunctivitis, upper limbal keratoconjunctivitis, filamentous keratoconjunctivitis, infectious keratitis, non-infectious keratitis, infectious conjunctivitis, Or it is useful as a preventive or therapeutic agent for keratoconjunctival disorders such as non-infectious conjunctivitis.
- it is useful as a therapeutic agent for corneal scarring and conjunctival scarring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Dermatology (AREA)
Abstract
Description
正常ウサギ角膜細胞を用い、Nishidaらの方法(Investigative Ophthalmology & Visual Science 42: 1247-1253(2001))に準じて、3次元コラーゲンゲル分解に対する被験化合物の抑制効果を評価した。
100ml中
RARγアゴニストA 100mg
塩化ナトリウム 800mg
ポリソルベート80 適量
リン酸水素二ナトリウム 適量
リン酸二水素ナトリウム 適量
滅菌精製水 適量
滅菌精製水にRARγアゴニストA及びそれ以外の上記成分を加え、これらを十分に混合して点眼液を調製する。RARγアゴニストA等の添加量を変えることにより、濃度が0.05%(W/V)、0.3%(W/V)、0.5%(W/V)又は1%(W/V)の点眼剤を調製できる。
100g中
RARγアゴニストA 0.3g
流動パラフィン 10.0g
白色ワセリン 適量
均一に溶融した白色ワセリン及び流動パラフィンに、RARγアゴニストAを加え、これらを十分に混合して後に徐々に冷却することで眼軟膏を調製する。RARγアゴニストA等の添加量を変えることにより、濃度が0.05%(W/W)、0.1%(W/W)、0.5%(W/W)又は1%(W/W)の眼軟膏を調製できる。
100mg中
RARγアゴニストA 1mg
乳糖 66.4mg
トウモロコシデンプン 20mg
カルボキシメチルセルロースカルシウム 6mg
ヒドロキシプロピルセルロース 6mg
ステアリン酸マグネシウム 0.6mg
RARγアゴニストA、トウモロコシデンプン及び乳糖を混合機中で混合し、その混合物にカルボキシメチルセルロースカルシウム及びヒドロキシプロピルセルロースを加えて造粒し、得られた顆粒を乾燥後整粒し、その整粒顆粒にステアリン酸マグネシウムを加えて混合し、打錠機で打錠する。また、RARγアゴニストA等の添加量を変えることにより、100mg中の含有量が0.1mg、10mg又は50mgの錠剤を調製できる。
初代結膜下線維芽細胞、初代角膜実質細胞を用い、Nishidaらの方法に準じて、3次元コラーゲンゲル収縮に対する被験化合物の抑制効果を評価した。
初代角膜実質細胞を用い、Nishidaらの方法に準じて、実施例1と同様の方法で3次元コラーゲンゲル分解に対する被験化合物の抑制効果を評価した。
タンパク質分解酵素であるマトリクスメタロプロテアーゼ(MMP)の分泌、発現がタイプIコラーゲンの分解に関与していると考えられている。そこで、RARγアゴニストAによるMMP-1、2、3及び9の発現及び活性化の抑制について調べた。
回収した培養液の上清を、10%ポリアクリルアミドゲルを用いたSDS-PAGEで展開した後、分離したタンパク質をニトロセルロース膜に転写した。次に、ニトロセルロース膜の非特異的部位をブロックし、抗ヒトMMP-1抗体(R&D systems社製)、抗ラビットMMP-3抗体(第一ファインケミカル社製)で4℃、24時間インキュベートし、ECL(登録商標)試薬(GE・ヘルスケア社製)を用いて検出した。
回収した培養液の上清を0.1%のゼラチンを含む10%ポリアクリルアミドゲルを用いたSDS-PAGEで展開した後、2.5%Triton X-100含むTBS溶液で室温にて1時間インキュベートした。インキュベート後のゲルをクマシーブリリアントブルー(和光純薬工業社製)の溶液にて染色し、5%メタノール-7.5%酢酸溶液(ナカライテスク社製)にて脱色した。
日本白色種雄性ウサギ(体重2.5-3.5kg、27匹)に対してケタミン及びキシラジン混合溶液の筋肉内投与により全身麻酔を施した。次に、0.4%塩酸オキシブプロカイン点眼液により局所麻酔を施した。さらに、片眼の角膜実質内に1%LPS(シグマアルドリッチ社製)を30μl注入した。なお、反対眼には注入しなかった。
Claims (5)
- RARγアゴニストを有効成分として含有する角結膜障害の治療剤。
- RARγアゴニストが、(E)-4-(2-{3-[(1H-ピラゾール-1-イル)メチル]-5,5,8,8-テトラメチル-5,6,7,8-テトラヒドロナフタレン-2-イル}ビニル)安息香酸、6-[3-(1-アダマンチル)-4-ヒドロキシフェニル]-2-ナフタレン酸、若しくは3-フルオロ-4-[2-ヒドロキシ-2-(5,5,8,8-テトラメチル-5,6,7,8-テトラヒドロナフタレン-2-イル)アセチルアミノ]安息香酸、そのエステル又はその塩である、請求項1に記載の治療剤。
- 角結膜障害が、角膜潰瘍、角膜上皮剥離、角膜炎、ドライアイ、結膜炎、慢性表層角膜炎、角膜糜爛、遷延性角膜障害、点状表層角膜症、角膜上皮欠損、結膜上皮欠損、乾性角結膜炎、上輪部角結膜炎、糸状角結膜炎、感染性角膜炎、非感染性角膜炎、感染性結膜炎、非感染性結膜炎、角膜瘢痕化、結膜瘢痕化からなる群から選択される、請求項1又は2に記載の治療剤。
- 投与形態が点眼投与又は経口投与である、請求項1~3のいずれかに記載の治療剤。
- 剤型が、点眼剤、眼軟膏、注射剤、錠剤、顆粒剤、細粒剤、散剤又はカプセル剤である、請求項1~4のいずれかに記載の治療剤。
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13854101.6A EP2918290B1 (en) | 2012-11-08 | 2013-11-07 | Therapeutic agent for keratoconjunctive disorders |
SG11201503612QA SG11201503612QA (en) | 2012-11-08 | 2013-11-07 | Therapeutic agent for keratoconjunctive disorders |
ES13854101T ES2834111T3 (es) | 2012-11-08 | 2013-11-07 | Agente terapéutico para trastornos queratoconjuntivos |
CN201380069723.0A CN105188753B (zh) | 2012-11-08 | 2013-11-07 | 角结膜病症的治疗剂 |
CN201811479227.3A CN109589324B (zh) | 2012-11-08 | 2013-11-07 | 角结膜病症的治疗剂 |
MX2015005842A MX363111B (es) | 2012-11-08 | 2013-11-07 | Agente terapeutico para trastornos de queratoconjuntivitis. |
US14/440,832 US9492431B2 (en) | 2012-11-08 | 2013-11-07 | Therapeutic agent for keratoconjunctive disorders |
BR112015010428A BR112015010428B1 (pt) | 2012-11-08 | 2013-11-07 | usos de uma composição |
CA2890424A CA2890424C (en) | 2012-11-08 | 2013-11-07 | Therapeutic agent for keratoconjunctive disorders |
RU2015121628A RU2659203C2 (ru) | 2012-11-08 | 2013-11-07 | Средство для лечения кератоконъюнктивальных заболеваний |
AU2013342882A AU2013342882B2 (en) | 2012-11-08 | 2013-11-07 | Therapeutic agent for keratoconjunctive disorders |
NZ708756A NZ708756A (en) | 2012-11-08 | 2013-11-07 | Therapeutic agent for keratoconjunctive disorders |
KR1020157013042A KR102173932B1 (ko) | 2012-11-08 | 2013-11-07 | 각결막 장해의 치료제 |
JP2014545578A JP6254529B2 (ja) | 2012-11-08 | 2013-11-07 | 角結膜障害の治療剤 |
ZA2015/04065A ZA201504065B (en) | 2012-11-08 | 2015-06-05 | Therapeutic agent for keratoconjunctive disorders |
HK16107218.3A HK1219224A1 (zh) | 2012-11-08 | 2016-06-22 | 角結膜病症的治療劑 |
US15/293,548 US9750721B2 (en) | 2012-11-08 | 2016-10-14 | Therapeutic agent for keratoconjunctive disorders |
US15/655,418 US10016395B2 (en) | 2012-11-08 | 2017-07-20 | Therapeutic agent for keratoconjunctive disorders |
US16/008,730 US10537556B2 (en) | 2012-11-08 | 2018-06-14 | Therapeutic agent for keratoconjunctive disorders |
AU2018217197A AU2018217197B2 (en) | 2012-11-08 | 2018-08-13 | Therapeutic agent for keratoconjunctive disorders |
US16/700,866 US11471440B2 (en) | 2012-11-08 | 2019-12-02 | Therapeutic agent for keratoconjunctive disorders |
US17/939,198 US20230255937A1 (en) | 2012-11-08 | 2022-09-07 | Therapeutic agent for keratoconjunctive disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012246373 | 2012-11-08 | ||
JP2012-246373 | 2012-11-08 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/440,832 A-371-Of-International US9492431B2 (en) | 2012-11-08 | 2013-11-07 | Therapeutic agent for keratoconjunctive disorders |
US15/293,548 Continuation US9750721B2 (en) | 2012-11-08 | 2016-10-14 | Therapeutic agent for keratoconjunctive disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014073209A1 true WO2014073209A1 (ja) | 2014-05-15 |
Family
ID=50684334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/006563 WO2014073209A1 (ja) | 2012-11-08 | 2013-11-07 | 角結膜障害の治療剤 |
Country Status (17)
Country | Link |
---|---|
US (6) | US9492431B2 (ja) |
EP (1) | EP2918290B1 (ja) |
JP (3) | JP6254529B2 (ja) |
KR (1) | KR102173932B1 (ja) |
CN (2) | CN109589324B (ja) |
AU (2) | AU2013342882B2 (ja) |
BR (1) | BR112015010428B1 (ja) |
CA (1) | CA2890424C (ja) |
CL (2) | CL2015001225A1 (ja) |
ES (1) | ES2834111T3 (ja) |
HK (1) | HK1219224A1 (ja) |
MX (2) | MX363111B (ja) |
NZ (1) | NZ708756A (ja) |
RU (1) | RU2659203C2 (ja) |
SG (2) | SG10201704687YA (ja) |
WO (1) | WO2014073209A1 (ja) |
ZA (1) | ZA201504065B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9750721B2 (en) | 2012-11-08 | 2017-09-05 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
US10702502B2 (en) | 2013-05-22 | 2020-07-07 | Yamaguchi University | Inhibitor for retinochoroidal disorders |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2740485B1 (en) * | 2012-12-07 | 2018-10-31 | Brightpulse Holding LTD. | Protein slurp-1 for use in the treatment of ocular diseases |
WO2017210792A1 (en) | 2016-06-08 | 2017-12-14 | Clementia Pharmaceuticals Inc. | Methods for treating heterotopic ossification |
US10980778B2 (en) | 2016-11-16 | 2021-04-20 | Clementia Pharmaceuticals Inc. | Methods for treating multiple osteochondroma (MO) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08333318A (ja) * | 1995-06-06 | 1996-12-17 | Bristol Myers Squibb Co | RARγ特異性レチノ安息香酸誘導体 |
WO2002028810A2 (en) | 2000-10-02 | 2002-04-11 | F. Hoffmann-La Roche Ag | Retinoids for the treatment of emphysema |
JP2007535563A (ja) * | 2004-04-30 | 2007-12-06 | アラーガン、インコーポレイテッド | レチノイド含有徐放性薬剤送達システム、ならびに関連する製造法 |
WO2008057930A2 (en) | 2006-11-02 | 2008-05-15 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with retinoic acid receptor agonists |
JP2009235031A (ja) | 2008-03-28 | 2009-10-15 | Nano Egg:Kk | 角膜組織の再生促進剤 |
JP2013536855A (ja) | 2010-09-01 | 2013-09-26 | トーマス・ジェファーソン・ユニバーシティ | 筋修復および再生のための組成物および方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08505852A (ja) | 1993-01-11 | 1996-06-25 | リガンド・ファーマシューティカルズ・インコーポレーテッド | レチノイドxレセプターに対する選択性を有する化合物 |
US5824685A (en) | 1995-02-01 | 1998-10-20 | The Johns Hopkins University School Of Medicine | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
US7514074B2 (en) | 1997-07-14 | 2009-04-07 | Osiris Therapeutics, Inc. | Cardiac muscle regeneration using mesenchymal stem cells |
US6204288B1 (en) * | 1999-03-08 | 2001-03-20 | The University Of Mississippi | 1,2-dithiolane derivatives |
US6313168B1 (en) | 1999-12-15 | 2001-11-06 | Allergan Sales, Inc. | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
US20030114482A1 (en) | 1999-12-15 | 2003-06-19 | Maurizio Pacifici | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
US20030125252A1 (en) | 2000-03-14 | 2003-07-03 | Underhill T. Michael | Compositions and methods for affecting osteogenesis |
DE60231888D1 (de) | 2001-09-18 | 2009-05-20 | Hoffmann La Roche | Substituierte harnstoff retinoid agonisten ii |
CA2460693C (en) | 2001-09-18 | 2010-12-07 | F. Hoffmann-La Roche Ag | Alkyl urea retinoid agonists i |
AUPR892501A0 (en) | 2001-11-16 | 2001-12-13 | Peter Maccallum Cancer Institute, The | Method of enhancing self renewal of stem cells and uses thereof |
US20050101581A1 (en) | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
JP2005206544A (ja) | 2004-01-23 | 2005-08-04 | Yasuyoshi Uchida | 筋肉再生剤 |
EP1868576A2 (en) | 2005-03-17 | 2007-12-26 | Elan Pharma International Limited | Injectable compositions of nanoparticulate immunosuppressive compounds |
US7345931B2 (en) | 2005-08-01 | 2008-03-18 | Infineon Technologies Ag | Maintaining internal voltages of an integrated circuit in response to a clocked standby mode |
JPWO2007037188A1 (ja) | 2005-09-27 | 2009-04-09 | 北海道公立大学法人 札幌医科大学 | 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬 |
AU2007233868A1 (en) | 2006-03-31 | 2007-10-11 | F. Hoffmann-La Roche Ag | Process for preparing retinoid compounds |
CA2651487A1 (en) | 2006-05-16 | 2007-11-29 | Vitae Pharmaceuticals, Inc. | Methods for treating chemotherapy and radiation therapy side effects |
CN101687031B (zh) * | 2006-10-27 | 2014-05-14 | 勒帕斯公司 | 用于治疗眼疾和眼病的组合物及方法 |
US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
WO2010071583A1 (en) | 2008-12-18 | 2010-06-24 | Astrazeneca Ab | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient |
US20120121546A1 (en) | 2009-02-05 | 2012-05-17 | Vishal Bhasin | Method of Producing Progenitor Cells from Differentiated Cells |
JP2013538830A (ja) | 2010-09-27 | 2013-10-17 | マイクロドース セラピューテクス,インコーポレイテッド | 吸入を用いる疾患治療のための方法及び組成物 |
US10485780B2 (en) | 2011-03-14 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of proliferative disorders |
US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
US8772273B2 (en) * | 2011-10-04 | 2014-07-08 | Quretino Therapeutics, Inc. | Formulations and uses of retinoic acid receptor selective agonists |
US9492431B2 (en) * | 2012-11-08 | 2016-11-15 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
BR112015029114B1 (pt) | 2013-05-22 | 2020-11-24 | Yamaguchi University | composição |
-
2013
- 2013-11-07 US US14/440,832 patent/US9492431B2/en active Active
- 2013-11-07 BR BR112015010428A patent/BR112015010428B1/pt active IP Right Grant
- 2013-11-07 SG SG10201704687YA patent/SG10201704687YA/en unknown
- 2013-11-07 SG SG11201503612QA patent/SG11201503612QA/en unknown
- 2013-11-07 WO PCT/JP2013/006563 patent/WO2014073209A1/ja active Application Filing
- 2013-11-07 CA CA2890424A patent/CA2890424C/en active Active
- 2013-11-07 ES ES13854101T patent/ES2834111T3/es active Active
- 2013-11-07 KR KR1020157013042A patent/KR102173932B1/ko active IP Right Grant
- 2013-11-07 RU RU2015121628A patent/RU2659203C2/ru active
- 2013-11-07 AU AU2013342882A patent/AU2013342882B2/en active Active
- 2013-11-07 MX MX2015005842A patent/MX363111B/es unknown
- 2013-11-07 EP EP13854101.6A patent/EP2918290B1/en active Active
- 2013-11-07 CN CN201811479227.3A patent/CN109589324B/zh active Active
- 2013-11-07 JP JP2014545578A patent/JP6254529B2/ja active Active
- 2013-11-07 NZ NZ708756A patent/NZ708756A/en unknown
- 2013-11-07 CN CN201380069723.0A patent/CN105188753B/zh active Active
-
2015
- 2015-05-07 CL CL2015001225A patent/CL2015001225A1/es unknown
- 2015-05-08 MX MX2019002526A patent/MX2019002526A/es active IP Right Grant
- 2015-06-05 ZA ZA2015/04065A patent/ZA201504065B/en unknown
-
2016
- 2016-06-22 HK HK16107218.3A patent/HK1219224A1/zh unknown
- 2016-10-14 US US15/293,548 patent/US9750721B2/en active Active
-
2017
- 2017-07-20 US US15/655,418 patent/US10016395B2/en active Active
- 2017-11-30 JP JP2017230426A patent/JP6462836B2/ja active Active
-
2018
- 2018-06-14 US US16/008,730 patent/US10537556B2/en active Active
- 2018-07-13 CL CL2018001915A patent/CL2018001915A1/es unknown
- 2018-08-13 AU AU2018217197A patent/AU2018217197B2/en active Active
- 2018-12-27 JP JP2018244364A patent/JP6744389B2/ja active Active
-
2019
- 2019-12-02 US US16/700,866 patent/US11471440B2/en active Active
-
2022
- 2022-09-07 US US17/939,198 patent/US20230255937A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08333318A (ja) * | 1995-06-06 | 1996-12-17 | Bristol Myers Squibb Co | RARγ特異性レチノ安息香酸誘導体 |
WO2002028810A2 (en) | 2000-10-02 | 2002-04-11 | F. Hoffmann-La Roche Ag | Retinoids for the treatment of emphysema |
JP2004510728A (ja) * | 2000-10-02 | 2004-04-08 | エフ.ホフマン−ラ ロシュ アーゲー | 気腫治療用新規レチノイド |
JP2007535563A (ja) * | 2004-04-30 | 2007-12-06 | アラーガン、インコーポレイテッド | レチノイド含有徐放性薬剤送達システム、ならびに関連する製造法 |
WO2008057930A2 (en) | 2006-11-02 | 2008-05-15 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with retinoic acid receptor agonists |
JP2009235031A (ja) | 2008-03-28 | 2009-10-15 | Nano Egg:Kk | 角膜組織の再生促進剤 |
JP2013536855A (ja) | 2010-09-01 | 2013-09-26 | トーマス・ジェファーソン・ユニバーシティ | 筋修復および再生のための組成物および方法 |
Non-Patent Citations (5)
Title |
---|
BERGMAN ET AL., ANALYTICAL CHEMISTRY, vol. 35, no. 12, 1963, pages 1961 - 1965 |
NISHIDA ET AL., INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 42, 2001, pages 1247 - 1253 |
SHIMONO K. ET AL., NATMED, vol. 17, no. 4, 2011, pages 454 - 460 |
SHI-YONG SUN ET AL.: "The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells", CANCER RESEARCH, vol. 62, no. 8, 15 April 2002 (2002-04-15), pages 2430 - 2436, XP055257430 * |
SUN SY ET AL., CANCER RESEARCH, vol. 62, no. 8, 2002, pages 2430 - 2436 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9750721B2 (en) | 2012-11-08 | 2017-09-05 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
US10016395B2 (en) | 2012-11-08 | 2018-07-10 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
US10537556B2 (en) | 2012-11-08 | 2020-01-21 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
US11471440B2 (en) | 2012-11-08 | 2022-10-18 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
US10702502B2 (en) | 2013-05-22 | 2020-07-07 | Yamaguchi University | Inhibitor for retinochoroidal disorders |
US11730718B2 (en) | 2013-05-22 | 2023-08-22 | Yamaguchi University | Inhibitor for retinochoroidal disorders |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6462836B2 (ja) | 角結膜障害の治療剤 | |
US11730718B2 (en) | Inhibitor for retinochoroidal disorders | |
JP2005047909A (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
NZ715245B2 (en) | Inhibitor for retinochoroidal disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201380069723.0 Country of ref document: CN |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13854101 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014545578 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2890424 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14440832 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: P584/2015 Country of ref document: AE |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/005842 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 20157013042 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015121628 Country of ref document: RU Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2013854101 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013854101 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013342882 Country of ref document: AU Date of ref document: 20131107 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015010428 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015010428 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150507 |